Press Releases

All Releases
View Summary Genomic Health Announces Second Quarter 2010 Financial Results and Business Progress
Aug 4, 2010 		PDF 19.2 KB
View Summary Genomic Health to Announce Second Quarter 2010 Financial Results and Host Conference Call on Wednesday, August 4, 2010
Jul 28, 2010 		PDF 8.1 KB
View Summary Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting
Jun 5, 2010 		PDF 16.7 KB
View Summary Genomic Health Announces Results From the Largest Genomic Analysis of Localized Clear Cell Renal Carcinoma at American Society of Clinical Oncology (ASCO) Annual Meeting
Jun 4, 2010 		PDF 11.1 KB
View Summary Genomic Health to Present at Two Upcoming Investor Conferences
Jun 2, 2010 		PDF 8.1 KB
View Summary Genomic Health Announces Six New Studies Including Four Oral Presentations Covering Breast, Colon and First Study in Renal Cancer Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 20, 2010 		PDF 13.9 KB
View Summary Genomic Health to Present at Citi Investment Research Global Health Care Conference
May 19, 2010 		PDF 7.7 KB
View Summary Genomic Health Announces First Quarter 2010 Financial Results and Business Progress
May 5, 2010 		PDF 20.3 KB
View Summary Genomic Health Announces New Data Reporting Clinical Usage Patterns of Oncotype DX(R) Among Breast Surgeons and Medical Oncologists
May 3, 2010 		PDF 12.5 KB
View Summary Genomic Health to Present at JMP Securities Research Conference
May 3, 2010 		PDF 8.0 KB
View Summary Genomic Health to Announce First Quarter 2010 Financial Results and Host Conference Call on Wednesday, May 5, 2010
Apr 28, 2010 		PDF 8.4 KB
View Summary Genomic Health Announces Exclusive Agreement With Palex Medical S.A. to Distribute the Oncotype DX(R) Breast Cancer Test in Spain and Portugal
Mar 25, 2010 		PDF 15.4 KB
View Summary Genomic Health Announces Publication of Study Using Oncotype DX® in Node-Negative and Node-Positive Breast Cancer Patients Treated With Aromatase Inhibitors
Mar 8, 2010 		PDF 15.0 KB
View Summary Genomic Health Develops New Methods for Whole Genome Expression Analysis of Standard Pathology Tumor Specimens
Mar 1, 2010 		PDF 12.8 KB
View Summary Genomic Health Announces Analysis Reinforcing Clinical Utility of Oncotype DX(R) Breast Cancer Test in Asia Pacific Patient Population
Feb 26, 2010 		PDF 12.4 KB
View Summary Genomic Health Announces Year-End 2009 Financial Results
Feb 3, 2010 		PDF 20.7 KB
View Summary Genomic Health to Announce Fourth Quarter and Year-End 2009 Financial Results and Host Conference Call on Wednesday, February 3
Jan 27, 2010 		PDF 8.1 KB
View Summary Genomic Health Announces Worldwide Availability of the Oncotype DX(R) Colon Cancer Test
Jan 21, 2010 		PDF 13.6 KB
View Summary Genomic Health Announces Publication of Data Demonstrating that the Oncotype DX® Breast Cancer Test Significantly Influences Breast Cancer Treatment Decisions, While Increasing Physician Confidence
Jan 12, 2010 		PDF 19.9 KB
View Summary Genomic Health Announces Preliminary Q4 and 2009 Revenue
Jan 7, 2010 		PDF 9.0 KB
Showing 1-20 of 161 Page: 1 2 3 ... 9  Next 20

Contact Information

For Investors:
650.569.2281
investors@genomichealth.com

For Media:
650.569.2215
media@genomichealth.com

  

Email Alerts

To sign-up to receive email alerts for press releases, stock information, new calendar events and/or SEC filings click here.

 

Shareholder Tools

  

DISCLAIMER

The information in the press releases should be considered accurate only as of the date of the document or presentation. We disclaim any obligation to supplement or update the information in these documents or presentations.


Forward-Looking Statements

This website contains forward-looking statements. Any statements contained in this website that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including risks and uncertainties associated with the reimbursement for and adoption of Oncotype DX; commercialization of any future tests; the nature and sources of our revenues; our dependence on collaborative relationships; the regulation of Oncotype DX or any future tests we may develop by the FDA; the attributes of our products; the benefits of personalized medicine and its ability to impact treatment decisions; the outcome and success of clinical trials; the applicability of clinical results to actual outcomes; the company's beliefs regarding the potential benefits that may be obtained from additional tests; and other factors detailed from time to time in Genomic Health's periodic filings with the Securities and Exchange Commission. Genomic Health, Inc. specifically disclaims any obligation to update any forward-looking statements.